NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Jupiter Endovascular

Jupiter Endovascular

Private
Menlo Park, CaliforniaHealthcare & Life Scienceshttps://jupiterendo.com/

Last Round

Series B

Oct 7, 2025

Total Funding Raised

$61M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Jupiter Endovascular is a medical technology company that develops catheter-based endovascular intervention systems using its proprietary Transforming Fixation (TFX) platform technology.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

endovascular devicecatheter technologypulmonary embolectomyperipheral artery diseasePADvascular interventioninterventional cardiologyfixation technologyendovascular surgerypulmonary embolismPEmedical device startupcatheter-based interventionclinical trialsmedtech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Jupiter Endovascular Comps

Public and private peers based on sector, stage, and business model.

Jupiter Endovascular comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Jupiter Endovascular Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BOct 7, 2025
SeedAug 15, 2024

Key People

Founding team and executive leadership

Carl St. Bernard

Chief Executive Officer

Executive Team

Fred Ong

CFO

Executive Team

Jupiter Endovascular Investors

Notable investors and investment history

Jupiter Endovascular investors
InvestorRounds
Senvest ManagementSeries B
LB InvestmentSeries B
Sonder CapitalSeed, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 6, 2026

    Open roles increased to 8, 17% of headcount.

  • Jun 30, 2026

    Grew 16% QoQ, from 49 to 57 employees.

Jupiter Endovascular Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Jupiter Endovascular Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Jupiter Endovascular's valuation, stock price, and market status.

Firmographic Details

HeadquartersMenlo Park, California
Employee Range57
Year Founded2024
Last FundingOct 7, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.